Zyrifa (denosumab biosimilar)
/ Zydus Lifesciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 10, 2025
Zydus Lifesciences on Wednesday, December 10, announced the launch of ‘Zyrifa’, a biosimilar version of Denosumab 120 mg administered subcutaneously, expanding its oncology portfolio with a therapy aimed at reducing skeletal-related events (SREs) in patients with advanced cancers
(CNBC-TV18)
Launch • Oncology
1 to 1
Of
1
Go to page
1